Sydney, Australia 1 June 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Michael Ironside as Director of Operations.
Dr Ironside has over 25 years of experience in senior roles in the highly regulated global pharmaceutical industry, including key positions in Europe, USA and Asia at contract development and manufacturing organisations (CDMOs) including Hovione and AMRI, as well as in the pharmaceutical and biotech sector at GSK, Anacor and Biosignal. During his career, Mike has contributed to the development of more than a dozen approved drugs including Alosetron, Viracept, Vyvanse, Tavaborole and Zejula.
Dr Ironside gained his PhD in Organic Chemistry from the University of Dundee in 1989 and then undertook a postdoctoral fellowship with Dr Richard Haynes at the University of Sydney.
Dr Ironside commented on his appointment: “I am pleased to be joining Clarity as Director of Operations and I’m looking forward to working with the team on a number of clinical trials in Australia and the U.S. I am certain that my experience in the pharmaceutical, biotech and CDMO sectors will be complimentary to shaping a solid operations strategy and robust supply and manufacturing processes to support Clarity’s strong focus on generating clinical data on a number of important products, such as SARTATE for neuroblastoma and SAR-bisPSMA for prostate cancer.”
Clarity’s Executive Chairman Dr Alan Taylor said: “We are excited to welcome Michael to our team and strengthen our operations function. With many important regulatory and clinical milestones achieved in the last year, it is now essential for Clarity to ensure seamless global manufacturing and supply to support the upcoming clinical trials. We are looking forward to further driving Clarity’s pipeline development with the ultimate goal of developing better treatments for children and adults with cancer.”
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
